BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

The European Commission has reportedly reached a deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to supply an additional four million COVID-19 vaccine doses be delivered in March.  According to Reuters, this additional supply deal is expected to ease border movement and tackle virus hotspots.

Pfizer/BioNTech To Supply Additional 4M COVID-19 Shots To Europe: Reuters

BioNTech Chief Executive Ugur Sahin said Tuesday the company could make 3 billion doses of its Pfizer-partnered Covid vaccine next year — and BNTX stock popped Wednesday. The post BioNTech Nears Buy Point On Predictions For 3 Billion Covid Vaccine Doses appeared first on Investor's Business Daily.

BioNTech Nears Buy Point On Predictions For 3 Billion Covid Vaccine Doses

In an interview with Bloomberg TV, CEO Ugur Sahin said BioNTech and Pfizer could dramatically increase output by 2022 if needed.

BioNTech Says It Could Supply 3 Billion Doses of Its Covid-19 Vaccine Next Year

Trailing other leading economies in Covid-19 vaccination, the European Commission said Pfizer and BioNTech have agreed to provide 4 million extra doses.

Europe's Lagging in Vaccination. Pfizer and BioNTech Agree to Provide 4 Million More Doses.

BioNTech SE (NASDAQ: BNTX) says it could have the capacity to make 3 billion doses of the COVID-19 vaccine it developed with Pfizer Inc (NYSE: PFE) in 2022, Bloomberg reports. BioNTech's CEO Ugur Sahin said that the increased manufacturing depends on demand and factors such as the requirement of the additional boost to vaccinations.

Pfizer, BioNTech Predict Increase In Capacity To 3B COVID-19 Vaccine Shots In 2022: Bloomberg

The European Commission said Wednesday that Pfizer and BioNTech will provide 4 million more doses of their coronavirus vaccine in the next two weeks. European Commission President Ursula von der Leyen said the doses are on top of planned dose deliveries.

European Commission says Pfizer and BioNTech to supply 4 million more coronavirus vaccine doses

The two companies' BNT162b2 seems to protect patients against the fast-spreading variant.

Study: Pfizer and BioNTech Vaccine Neutralizes Brazil Coronavirus Variant

Moderna

A year ago, a handful of vaccine stocks emerged out of relative obscurity as a deadly pandemic began claiming the lives of millions. But these stocks don't intend to stop at Covid-19.

The Pandemic Proved Their Worth — What's Next For Moderna, BioNTech?

The global tally of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 117 million on Tuesday, as a study found the vaccine developed by Pfizer Inc. and German partner BioNTech SE is effective in neutralizing the highly infectious new variant that was first detected in Brazil.

Coronavirus Update: Global tally of COVID cases tops 117 million as study finds Pfizer-BioNTech vaccine works against Brazil variant

Pfizer and BioNTech's Covid-19 vaccine was able to neutralize a coronavirus variant first identified in Brazil in a laboratory test published Monday. In response, BNTX stock popped Tuesday.

Pfizer, BioNTech Covid Vaccine Takes Down Brazil Variant In Lab Test

Pfizer (PFE) and Valneva are jointly developing a vaccine candidate for Lyme disease. It is the only candidate in clinical development.

Pfizer/Valneva Lyme Disease Vaccine Candidate Enters Phase II

Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.

Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains

The COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) works on the Brazil variant, according to a new study. Scientists took blood samples from people who had already received the jab and analysed it against a lab-made reconstruction of the virus.

Coronavirus: Pfizer/BioNTech vaccine works on Brazil variant, study shows

According to a lab study published in the New England Journal of Medicine, Pfizer Inc (NYSE: PFE)/BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine can neutralize a new variant of the coronavirus in Brazil, reported Reuters. The scientists said the neutralizing ability was roughly equivalent to the vaccine's effect on a previous version of the virus from last year.

Pfizer/BioNTech COVID-19 Jab Neutralizes Virus Variant In Brazil: Reuters

Researchers developed an engineered version of the COVID-19 mutation and found that blood samples taken from people who received the vaccine were able to neutralize the variant, according to the study published in the New England Journal of Medicine on Monday.

The New York Post: Pfizer-BioNTech vaccine neutralizes Brazil COVID-19 variant, study shows

The Pfizer/BioNTech coronavirus vaccine was able to combat the Brazil variant of COVID-19, it has been revealed.

Pfizer/BioNTech vaccine shows promise against Brazil coronavirus variant in laboratory testing

Russian intelligence officials are attempting to cast doubt on the Pfizer coronavirus vaccine, according to a new report from the Wall Street Journal.  Four publications acting as fronts for Russian intelligence are disseminating information that questions the efficacy and safety of the Pfizer vaccine, State Department officials told the Journal.

Russian intelligence has reportedly launched a disinformation campaign attacking the Pfizer COVID-19 vaccine

The opportunity is bigger than it might at first appear.

Are Pregnant Women a Big Market for Pfizer and BioNTech's Vaccine?

How Worried Should Investors Be About the South African Coronavirus Variant?

AstraZeneca

CureVac B.V

Johnson & Johnson

Novavax

Sinovac Biotech

The companies in line for the biggest gains – and the shareholders who have already made fortunes

From Pfizer to Moderna: who's making billions from Covid-19 vaccines?

Pfizer Inc's (NYSE: PFE) McPherson, Kansas plant used to accelerate production of its COVID-19 vaccine was cited by federal inspectors last year for repeated quality-control violations, reports Bloomberg. The FDA inspectors visited the plant at the end of 2019 into January 2020 and found that the company released medications for sale after failing to review quality issues thoroughly that arose in routine testing.

Pfizer's Plant For Boosting COVID-19 Vaccine Production Has Been Rebuked For Repeat Quality Offenses: Bloomberg

The key ingredients are here for a multi-bagger over the next decade and beyond.

Is BioNTech Stock a Buy?

Should You Be Concerned About mRNA COVID Vaccines?

Figures in a research paper from Public Health England showed how vaccines can significantly reduce hospitalizations in the elderly.

Real-world data shows Pfizer's Covid vaccine is giving 'very strong' results after one dose

France revises its stance and approves the AstraZeneca–Oxford vaccine for the over-65s.

News for BioNTech SE Stock (BNTX)